HRP20000255A2 - Use of thiazolidinediones for the treatment of hyperglycaemia - Google Patents
Use of thiazolidinediones for the treatment of hyperglycaemia Download PDFInfo
- Publication number
- HRP20000255A2 HRP20000255A2 HR20000255A HRP20000255A HRP20000255A2 HR P20000255 A2 HRP20000255 A2 HR P20000255A2 HR 20000255 A HR20000255 A HR 20000255A HR P20000255 A HRP20000255 A HR P20000255A HR P20000255 A2 HRP20000255 A2 HR P20000255A2
- Authority
- HR
- Croatia
- Prior art keywords
- hyperglycemia
- compound
- pharmaceutically acceptable
- insulin sensitiser
- glucose level
- Prior art date
Links
- 201000001421 hyperglycemia Diseases 0.000 title claims description 43
- 238000011282 treatment Methods 0.000 title claims description 14
- 229940123464 Thiazolidinedione Drugs 0.000 title claims description 11
- 150000001467 thiazolidinediones Chemical class 0.000 title description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 35
- 102000004877 Insulin Human genes 0.000 claims description 32
- 108090001061 Insulin Proteins 0.000 claims description 32
- 229940125396 insulin Drugs 0.000 claims description 32
- 231100000489 sensitizer Toxicity 0.000 claims description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 17
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 11
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000007410 oral glucose tolerance test Methods 0.000 claims description 5
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229960001641 troglitazone Drugs 0.000 claims description 3
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 3
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 2
- 229950009226 ciglitazone Drugs 0.000 claims description 2
- 229950002375 englitazone Drugs 0.000 claims description 2
- 229960005095 pioglitazone Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000002641 glycemic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721693.1A GB9721693D0 (en) | 1997-10-13 | 1997-10-13 | Novel treatment |
| PCT/GB1998/003064 WO1999018943A1 (en) | 1997-10-13 | 1998-10-12 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000255A2 true HRP20000255A2 (en) | 2001-02-28 |
Family
ID=10820482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000255A HRP20000255A2 (en) | 1997-10-13 | 2000-05-02 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1023056A1 (xx) |
| JP (1) | JP2001519382A (xx) |
| KR (1) | KR20010024481A (xx) |
| CN (1) | CN1281359A (xx) |
| AP (1) | AP2000001787A0 (xx) |
| AU (1) | AU9547098A (xx) |
| BG (1) | BG104404A (xx) |
| BR (1) | BR9815219A (xx) |
| CA (1) | CA2306086A1 (xx) |
| CZ (1) | CZ20001297A3 (xx) |
| EA (1) | EA002659B1 (xx) |
| GB (1) | GB9721693D0 (xx) |
| HR (1) | HRP20000255A2 (xx) |
| HU (1) | HUP0003922A3 (xx) |
| ID (1) | ID24521A (xx) |
| IL (1) | IL135513A0 (xx) |
| NO (1) | NO20001898L (xx) |
| NZ (1) | NZ503862A (xx) |
| OA (1) | OA11683A (xx) |
| PL (1) | PL339813A1 (xx) |
| SK (1) | SK5312000A3 (xx) |
| TR (1) | TR200000958T2 (xx) |
| WO (1) | WO1999018943A1 (xx) |
| YU (1) | YU28800A (xx) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
-
1997
- 1997-10-13 GB GBGB9721693.1A patent/GB9721693D0/en not_active Ceased
-
1998
- 1998-10-12 AP APAP/P/2000/001787A patent/AP2000001787A0/en unknown
- 1998-10-12 HU HU0003922A patent/HUP0003922A3/hu unknown
- 1998-10-12 YU YU28800A patent/YU28800A/sh unknown
- 1998-10-12 CZ CZ20001297A patent/CZ20001297A3/cs unknown
- 1998-10-12 PL PL98339813A patent/PL339813A1/xx unknown
- 1998-10-12 BR BR9815219-0A patent/BR9815219A/pt not_active Application Discontinuation
- 1998-10-12 CA CA002306086A patent/CA2306086A1/en not_active Abandoned
- 1998-10-12 NZ NZ503862A patent/NZ503862A/xx unknown
- 1998-10-12 AU AU95470/98A patent/AU9547098A/en not_active Abandoned
- 1998-10-12 JP JP2000515578A patent/JP2001519382A/ja active Pending
- 1998-10-12 TR TR2000/00958T patent/TR200000958T2/xx unknown
- 1998-10-12 SK SK531-2000A patent/SK5312000A3/sk unknown
- 1998-10-12 ID IDW20000669A patent/ID24521A/id unknown
- 1998-10-12 CN CN98812083A patent/CN1281359A/zh active Pending
- 1998-10-12 IL IL13551398A patent/IL135513A0/xx unknown
- 1998-10-12 OA OA1200000108A patent/OA11683A/en unknown
- 1998-10-12 WO PCT/GB1998/003064 patent/WO1999018943A1/en not_active Application Discontinuation
- 1998-10-12 EP EP98949086A patent/EP1023056A1/en not_active Withdrawn
- 1998-10-12 KR KR1020007003934A patent/KR20010024481A/ko not_active Application Discontinuation
- 1998-10-12 EA EA200000419A patent/EA002659B1/ru not_active IP Right Cessation
-
2000
- 2000-04-12 NO NO20001898A patent/NO20001898L/no not_active Application Discontinuation
- 2000-05-02 HR HR20000255A patent/HRP20000255A2/hr not_active Application Discontinuation
- 2000-05-05 BG BG104404A patent/BG104404A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9815219A (pt) | 2001-01-02 |
| JP2001519382A (ja) | 2001-10-23 |
| IL135513A0 (en) | 2001-05-20 |
| OA11683A (en) | 2005-01-12 |
| AU9547098A (en) | 1999-05-03 |
| CN1281359A (zh) | 2001-01-24 |
| HUP0003922A3 (en) | 2001-12-28 |
| AP2000001787A0 (en) | 2000-06-30 |
| GB9721693D0 (en) | 1997-12-10 |
| WO1999018943A1 (en) | 1999-04-22 |
| EA200000419A1 (ru) | 2000-10-30 |
| CA2306086A1 (en) | 1999-04-22 |
| BG104404A (bg) | 2000-12-29 |
| YU28800A (sh) | 2003-02-28 |
| CZ20001297A3 (cs) | 2001-08-15 |
| KR20010024481A (ko) | 2001-03-26 |
| NZ503862A (en) | 2003-01-31 |
| EP1023056A1 (en) | 2000-08-02 |
| PL339813A1 (en) | 2001-01-02 |
| NO20001898L (no) | 2000-06-09 |
| TR200000958T2 (tr) | 2000-08-21 |
| ID24521A (id) | 2000-07-20 |
| EA002659B1 (ru) | 2002-08-29 |
| SK5312000A3 (en) | 2000-09-12 |
| NO20001898D0 (no) | 2000-04-12 |
| HUP0003922A2 (hu) | 2001-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005213273A (ja) | チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療 | |
| JP2005247865A (ja) | チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療 | |
| KR20010021952A (ko) | 티아졸리딘디온, 인슐린 분비촉진제 및 알파 글루코시다제억제제를 사용한 당뇨병의 치료 | |
| BG103966A (bg) | Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата | |
| KR20010013840A (ko) | 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료 | |
| US20020137773A1 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| HRP20000256A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| HRP20000255A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| US20010031776A1 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| MXPA00003634A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| MXPA00003633A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| CZ299801B6 (cs) | Farmaceutický prostredek s postupným uvolnováním a lécivo pro lécení diabetes mellitus typu 2 a stavu souvisejících s diabetes mellitus | |
| AU4586902A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| AU4587002A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| MXPA00000633A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
| MXPA01004853A (en) | Novel method of treatment | |
| MXPA99012098A (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
| MXPA00000631A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| MXPA99012078A (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| MXPA00000655A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
| CZ2000174A3 (cs) | Farmaceutický prostředek proti diabetů mellitus a stavům s ním spojeným |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20041004 Year of fee payment: 7 |
|
| OBST | Application withdrawn |